Second allografts for relapsed hematologic malignancies: feasibility of using a different donor.
Publication/Presentation Date
2-1-2005
Abstract
A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed. If the original donor is not available, a different donor may have to be considered. We report our experience of performing a second allogeneic HSCT using a different donor in patients with relapsed leukemia and lymphoma. In a 5-year period, six patients underwent a second allograft with myeloablative conditioning using a different donor. Four of these were retransplanted using a matched-unrelated donor. Four of the patients (67%) remain progression-free at a median follow-up of 32 months (range 3-72). There were no cases of transplant-related mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available.
Volume
35
Issue
3
First Page
261
Last Page
264
ISSN
0268-3369
Published In/Presented At
Duus, J. E., Stiff, P. J., Choi, J., Parthasarathy, M., Rodriguez, T., & Toor, A. A. (2005). Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone marrow transplantation, 35(3), 261–264. https://doi.org/10.1038/sj.bmt.1704761
Disciplines
Medicine and Health Sciences
PubMedID
15558039
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article